Lynn Stockwell - Feb 18, 2025 Form 4 Insider Report for Drugs Made In America Acquisition Corp. (DMAA)

Role
CEO and Exe. Chair of Board, Director, 10%+ Owner
Signature
/s/ Lynn Stockwell
Stock symbol
DMAA
Transactions as of
Feb 18, 2025
Transactions value $
$0
Form type
4
Date filed
2/18/2025, 09:54 PM
Previous filing
Feb 4, 2025
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DMAA Ordinary shares Purchase +30K +0.72% 4.19M Feb 18, 2025 See Footnotes F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DMAA Rights to receive ordinary shares Purchase +30K +7.5% 430K Feb 18, 2025 Ordinary shares 30K See Footnotes F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Reflects the 30,000 private units acquired by Drugs Made In America Acquisition LLC, the Issuer's sponsor. Each private unit consists of one ordinary share and one right to receive one-eighth (1/8) of an ordinary share upon the consummation of an initial business combination. The private units were purchased at $10 per unit for an aggregate purchase price of $300,000. Lynn Stockwell is the managing member of the sponsor and has voting and dispositive power over the securities held of record by the sponsor. Ms. Stockwell disclaims any beneficial ownership of the securities held by the sponsor, except to the extent of her pecuniary interest therein.
F2 The rights convert automatically into ordinary shares at the completion of the Issuer's initial business combination.